Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence
Since Banting and Best isolated insulin in the 1920s, dramatic progress has been made in the treatment of type 1 diabetes mellitus (T1DM). However, dose titration and timely injection to maintain optimal glycemic control are often challenging for T1DM patients and their families because they require frequent blood glucose checks. In recent years, technological advances in insulin pumps and continuous glucose monitoring systems have created paradigm shifts in T1DM care that are being extended to develop artificial pancreas systems (APSs). Numerous studies that demonstrate the superiority of glycemic control offered by APSs over those offered by conventional treatment are still being published, and rapid commercialization and use in actual practice have already begun. Given this rapid development, keeping up with the latest knowledge in an organized way is confusing for both patients and medical staff. Herein, we explore the history, clinical evidence, and current state of APSs, focusing on various development groups and the commercialization status. We also discuss APS development in groups outside the usual T1DM patients and the administration of adjunct agents, such as amylin analogues, in APSs..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:45 |
|---|---|
| Enthalten in: |
Diabetes & Metabolism Journal - 45(2021), 6, Seite 813-839 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Sun Joon Moon [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| doi: |
10.4093/dmj.2021.0177 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ051525054 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ051525054 | ||
| 003 | DE-627 | ||
| 005 | 20230308161803.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230227s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.4093/dmj.2021.0177 |2 doi | |
| 035 | |a (DE-627)DOAJ051525054 | ||
| 035 | |a (DE-599)DOAJ5d7d1bb4460740ed8982101ff13b0d9e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a RC648-665 | |
| 100 | 0 | |a Sun Joon Moon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Current Advances of Artificial Pancreas Systems: A Comprehensive Review of the Clinical Evidence |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Since Banting and Best isolated insulin in the 1920s, dramatic progress has been made in the treatment of type 1 diabetes mellitus (T1DM). However, dose titration and timely injection to maintain optimal glycemic control are often challenging for T1DM patients and their families because they require frequent blood glucose checks. In recent years, technological advances in insulin pumps and continuous glucose monitoring systems have created paradigm shifts in T1DM care that are being extended to develop artificial pancreas systems (APSs). Numerous studies that demonstrate the superiority of glycemic control offered by APSs over those offered by conventional treatment are still being published, and rapid commercialization and use in actual practice have already begun. Given this rapid development, keeping up with the latest knowledge in an organized way is confusing for both patients and medical staff. Herein, we explore the history, clinical evidence, and current state of APSs, focusing on various development groups and the commercialization status. We also discuss APS development in groups outside the usual T1DM patients and the administration of adjunct agents, such as amylin analogues, in APSs. | ||
| 650 | 4 | |a blood glucose self-monitoring | |
| 650 | 4 | |a diabetes mellitus, type 1 | |
| 650 | 4 | |a hypoglycemia | |
| 650 | 4 | |a insulin infusion systems | |
| 650 | 4 | |a pancreas, artificial | |
| 650 | 4 | |a wearable electronic devices | |
| 653 | 0 | |a Diseases of the endocrine glands. Clinical endocrinology | |
| 700 | 0 | |a Inha Jung |e verfasserin |4 aut | |
| 700 | 0 | |a Cheol-Young Park |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Diabetes & Metabolism Journal |d Korean Diabetes Association, 2016 |g 45(2021), 6, Seite 813-839 |w (DE-627)DOAJ00014374X |x 22336087 |7 nnns |
| 773 | 1 | 8 | |g volume:45 |g year:2021 |g number:6 |g pages:813-839 |
| 856 | 4 | 0 | |u https://doi.org/10.4093/dmj.2021.0177 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/5d7d1bb4460740ed8982101ff13b0d9e |z kostenfrei |
| 856 | 4 | 0 | |u http://www.e-dmj.org/upload/pdf/dmj-2021-0177.pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2233-6079 |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2233-6087 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 45 |j 2021 |e 6 |h 813-839 | ||